Mijung Lee et al. discovered that Beta-Lapachone improves HD phenotypes by increasing Sirt1 expression, CREB phosphorylation, and PGC-1α deacetylation, with oral administration of Beta-Lapachone to R6/2 HD mice resulting in enhancements in behavioral phenotypes related to HD, such as impairment of rota-rod performance and increase of clasping behavior, as well as changes in Sirt1 expression, CREB phosphorylation, and PGC-1α deacetylation, highlighting Beta-Lapachone’s potential as a therapeutic candidate for the treatment of HD-associated phenotypes [72]. This evidence concerns the gene PPARGC1A and ring chromosome 6.